CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis

[1] Anderson JL(2013)2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction J Am Coll Cardiol 61 e179-e347

[2] Adams CD(2013)2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines J Am Coll Cardiol 61 e78-140

[3] Antman EM(2015)Novel antiplatelet agents in acute coronary syndrome Nat Rev Cardiol 12 30-47

[4] O’Gara PT(2014)Resistance to antiplatelet drugs: what progress has been made? Expert Opin Pharmacother 15 2553-2564

[5] Kushner FG(2015)Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments Lancet 386 281-291

[6] Ascheim DD(2012)Meta-analyses of the association between cytochrome Heart 98 100-108

[7] Franchi F(2011) loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel Clin Pharmacol Ther 90 328-332

[8] Angiolillo DJ(2010)Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 ( JAMA 304 1821-1830

[9] Tantry US(2007)) genotype and clopidogrel therapy N Engl J Med 357 2001-2015

[10] Gesheff M(2009)Reduced-function N Engl J Med 361 1045-1057

[1] Anderson JL(2013)2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction J Am Coll Cardiol 61 e179-e347

[2] Adams CD(2013)2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines J Am Coll Cardiol 61 e78-140

[3] Antman EM(2015)Novel antiplatelet agents in acute coronary syndrome Nat Rev Cardiol 12 30-47

[4] O’Gara PT(2014)Resistance to antiplatelet drugs: what progress has been made? Expert Opin Pharmacother 15 2553-2564

[5] Kushner FG(2015)Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments Lancet 386 281-291

[6] Ascheim DD(2012)Meta-analyses of the association between cytochrome Heart 98 100-108

[7] Franchi F(2011) loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel Clin Pharmacol Ther 90 328-332

[8] Angiolillo DJ(2010)Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 ( JAMA 304 1821-1830

[9] Tantry US(2007)) genotype and clopidogrel therapy N Engl J Med 357 2001-2015

[10] Gesheff M(2009)Reduced-function N Engl J Med 361 1045-1057